Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Dapagliflozin/metformin (Primary) ; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 25 Jun 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Jun 2025.
- 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2024 Planned End Date changed from 30 Apr 2025 to 30 Jun 2025.